Robert Anthony Schaefer, M.D.

Robert Schaefer

Dr. Schaefer is an Associate Attending Physician at the NewYork-Presbyterian Hospital Weill Cornell Medical Center andAssociate Professor of Clinical Medicine at the Weill Medical College of Cornell University. He specializes in general GI including gallstones and stomach and intestinal diseasesas well as endoscopy and hepatitis.

Dr. Schaefer received his medical degree from Columbia University, College of Physicians and Surgeons, completed an internship in internal medicine at the University of Vermont, and his fellowship at Cornell University Medical College. He has a large internal medicine and gastroenterology practice at Cornell. He has been a clinical consultant for clinical trials of the efficacy of the Hepatitis A and B vaccine.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • * Empire Blue Cross/Blue Shield [EPO]
  • * Empire Blue Cross/Blue Shield [PPO]
  • * Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • * Empire Blue Cross/Blue Shield [HMO]
  • Fidelis Care
  • Health First
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]


Bibliography:      Articles

1.   Schaefer, R.A. and Goldstein, M. J. Gastric and esophageal telangiectasis. Gastrointestinal Endoscopy 19:192, 1973.

2.   Reilly, P.A., Catino, D. and Schaefer, R.A. Duodenal ulcer in rural Haiti. L. Trop. Med. Hygiene 78:227, 1975

3.   Trepo, C.G., Vitvitski, L., Neurath, R., Hashimoto, N., Schaefer, R.A. and Prince, A.M. Detection of e Antigen by immunofluorescence in the cytoplasm of hepatocytes of HbsAg carries (letter) Lance 1:486, 1976

4.   Trepo, C.G., Magnius, L. O., Schaefer, R.A. and Prince, A.M. Detection and significance of e Antigen and Anti-e antibody in Hepatitis B infection. Gastroenterology 71:804, 1976

5.   Cherubin, C., Schaefer, R.A., Rosenthal, W. S., et. al. The natural history of liver disease in former drug users. Am. J. Med. Sci. 272:244, 1976

6.   Schaefer, R.A. “Chronic active hepatitis”, L.A. Wallis and M. Nydick, (editors), in Cornell Medical Updates, Vol. 1, 1977

7.   Schaefer, R.A. Management of chronic active hepatitis. Drug Therapy, 6:17-26, 1981

8.   Lachin, J. M., Marks, J. W., Schoenfield, L. J., et. al. Design and methodological considerations in the National Cooperative Gallstone Study: a multi center clinical trial. Controlled Clinical Trials. 2:177-229, 1981

9.   Schoenfield, L. J., Lachin, J. M., et. al. Chenodiol (chenodeoxycholic Acid) for dissolution of gallstones: The National Cooperative Gallstone Study. Annals Int. Med. 95:257-282, 1981.

10.   Fisher, R. L., Anderson, D. W., Boyer, J. L. et. at. A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis. The National Cooperative Gallstone Study. Hepatology 2:187-201, 1982

11.   Schaefer, R.A. and Kreek, M. J. “Chenodeoxycholic acid in the management of gallstones”; in J. R.. Bianchine (editor), “Recent Advances in Clinical Therapeutics”, 1982

12.   Albers, J. J., Grundy, S.M., Cleary, P.A., et. al. National Cooperative Gallstone

Study: The effect of chenodeoxycholic acid on lipoproteins and apolipoproteins.    Gastroenterology 82:638-464, 1982

13.   Schaefer, R.A. “Diarrhea: current concepts of pathophysiology”, L.A. Wallis and M. Nydick (editors), in “Cornell Medical Update”, Vol. 3, 1982.

14.   Hofmann, A.F., Grundy, S.M., Lachin, J. M. et. al. The National Cooperative Gallstone Study: Pretreatment biliary lipid composition in white patients with radiolucent gallstones, 1981.

15.   Phillips, M. J., Fisher, R. L., Anderson, D. W., et. al. The National Cooperative Gallstone Study. Ultrastructural evidence of intrahepatic cholestasis before and after chenodeoxycholic acid therapy in patients with cholelithiasis. Submitted for publication, 1982.

16.   Kreek,M.J., Schaefer, R.A., Hahn, E.F., Fishman, J. Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet 1,261-262, 1983

17.   Ergun,G., Schaefer, R.A. “Gastrointestinal Aspects of Epidermolysis Bullosa” in “Epidermolysis Bullosa”, A.N. Lin and D.M. Carter, editors, 1992, pp. 169-184

Bibliography:   Abstracts

1.   Schaefer, R.A., Javitt, N.B., Finlayson, N.D.C., and Prince, A.M. Serum Chenodeoxycholate Levels in Hepatitis B Antigen Carriers. Gastroenterology 66:865, 1974

2.   Schaefer, R.A., Finlayson, N.D.C., Prince, A.M. Liver disease in Asymptomatic Hepatitis B Antigen Carriers. J. Clin . Invest. 53:714, 1974 (Presented at Joint meeting of AFCR/ASCI, May 5, 1974).

3.   Schaefer, R.A., Finlayson, N.D.C., Prince, A.M., Fauconnet, M., and Vitvitski, L.: Lymphocyte Transformation in HbsAg Carriers. Hepatitis Scientific Memoranda. H - 728, 1974.

4.   Trepo, C., Schaefer, R.A., Vitvitski, L., Prince, A.M.: Hepatitis B Core and Surface Antigen, Immunoglobulins, and Complement in Liver Biopsies: Detection by Direct Immunoflourescence. Clin. Research 23:258 A, 1975 (Presented at Joint meeting of AFCR/ASCI, May 4, 1975)

5.   Trepo, C. Magnius, L., Schaefer, R.A., Prince, A.M.,: Detection and Clinical Significance of e Antigen and Anti-e Antibody in Hepatitis B Surface Antigen Carriers. Gastroenterology 69: 872, 1975 (Presented at annual meeting of AASLD. November 3-4, 1975).

6.   Solny, M., Kassan, S.S., Kammerer, W.H., Lockshin, M.D., and Schaefer, R.A.: Gastrointestinal Perforation Associated with Corticosteroid Theraphy. Gastroenterology 72:1134, 1977.

7.   Thistle, J. L., Clearly, P.A., Lachin, J. M., et. al. The natural history of untreated Cholelithiasis during the National Cooperative Gallstone Study. Gastroenterology 82:1197, 1982. (Presented at the annual meeting of AGA, May 18, 1982).

8.   Marks, J. W. Schoenfield, L. J., and the Steering Committee. The National Cooperative Gallstone Study: Further therapy with chenodiol in patients who had partial dissolution of gallstone after two years. Gastroenterology 82:1124, 1982 (Presented at annual meeting of AGA, May 19, 1982).

9.   Schwartz, S.J., Lan, S.P., Soloway, R.D., et. al. Predicting gallstone dissolution in patients treated with chenodiol. Gastroenterology 82:1173, 1982. (Presented at annual meeting of AGA, May 16, 1982).

10.   Kreek, M. J., Lahita, R., Schaefer, R.A., Anderson, K., and Bradlow, H.L. Decreased 2-hydroxylation of estadiol in chronic liver disease. J. Clin. Endo. Metab., in press(1982). Presented at annual meeting of Endocrine Society, June 16-18, 1982

Honors and Awards

Committees   (Selected)

1)   Committees on Human Rights in Research (Institutional Review Board)

Cornell-New York Hospital

Medical Center

Member, 2002 -

Member, 1975 - 1979, 2002-

Vice Chairman, 1978 - 1979

2)   Committee on Morbidity and Mortality

Cornell-New York Hospital

Medical Center

1979 - 1983

3)   Special Committee on Prescription Practices      

Medical Society of the County of

New York (1978 - 1981)

4)   Steering Committee

National Cooperative Gallstone Study

1979 - 1981

5)   Intersociety Committee on Human Experimentation in Digestive Disease

(AASLD representative)

1980 - 1982

6)   American Gastroenterological Association:

Local Committee for 1981 National Meeting      

7)   Greater New York Blood Program Task Force on ALT Testing

1981 - 1984